<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Smoking and the risks of adult diseases • tobalcepi</title>
<!-- jquery --><script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js" integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin="anonymous"></script><!-- Bootstrap --><link href="https://cdnjs.cloudflare.com/ajax/libs/bootswatch/3.4.0/flatly/bootstrap.min.css" rel="stylesheet" crossorigin="anonymous">
<script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.4.1/js/bootstrap.min.js" integrity="sha256-nuL8/2cJ5NDSSwnKD8VqreErSWHtnEP9E7AySL+1ev4=" crossorigin="anonymous"></script><!-- bootstrap-toc --><link rel="stylesheet" href="../bootstrap-toc.css">
<script src="../bootstrap-toc.js"></script><!-- Font Awesome icons --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/all.min.css" integrity="sha256-mmgLkCYLUQbXn0B1SRqzHar6dCnv9oZFPEC1g1cwlkk=" crossorigin="anonymous">
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/v4-shims.min.css" integrity="sha256-wZjR52fzng1pJHwx4aV2AO3yyTOXrcDW7jBpJtTwVxw=" crossorigin="anonymous">
<!-- clipboard.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><!-- headroom.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/headroom.min.js" integrity="sha256-AsUX4SJE1+yuDu5+mAVzJbuYNPHj/WroHuZ8Ir/CkE0=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/jQuery.headroom.min.js" integrity="sha256-ZX/yNShbjqsohH1k95liqY9Gd8uOiE1S4vZc+9KQ1K4=" crossorigin="anonymous"></script><!-- pkgdown --><link href="../pkgdown.css" rel="stylesheet">
<script src="../pkgdown.js"></script><meta property="og:title" content="Smoking and the risks of adult diseases">
<meta property="og:description" content="tobalcepi">
<!-- mathjax --><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script><!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]-->
</head>
<body data-spy="scroll" data-target="#toc">
    <div class="container template-article">
      <header><div class="navbar navbar-default navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar" aria-expanded="false">
        <span class="sr-only">Toggle navigation</span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <span class="navbar-brand">
        <a class="navbar-link" href="../index.html">tobalcepi</a>
        <span class="version label label-default" data-toggle="tooltip" data-placement="bottom" title="Released version">1.0.2</span>
      </span>
    </div>

    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
<li>
  <a href="../index.html">
    <span class="fas fa fas fa-home fa-lg"></span>
     
  </a>
</li>
<li>
  <a href="../reference/index.html">Reference</a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-expanded="false">
    Articles
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
<li>
      <a href="../articles/alc_partially_attrib_acute.html">Risk of acute conditions partially-attributable to alcohol</a>
    </li>
    <li>
      <a href="../articles/alcohol-disease-risks.html">Alcohol consumption and the risks of adult diseases</a>
    </li>
    <li>
      <a href="../articles/attributable-fractions.html">Population attributable fractions of disease</a>
    </li>
    <li>
      <a href="../articles/smoking-disease-risks.html">Smoking and the risks of adult diseases</a>
    </li>
    <li>
      <a href="../articles/tobacco-alcohol-disease-interactions.html">Tobacco and alcohol interactions in disease risk</a>
    </li>
  </ul>
</li>
      </ul>
<ul class="nav navbar-nav navbar-right"></ul>
</div>
<!--/.nav-collapse -->
  </div>
<!--/.container -->
</div>
<!--/.navbar -->

      

      </header><div class="row">
  <div class="col-md-9 contents">
    <div class="page-header toc-ignore">
      <h1 data-toc-skip>Smoking and the risks of adult diseases</h1>
            
      
      
      <div class="hidden name"><code>smoking-disease-risks.Rmd</code></div>

    </div>

    
    
<div id="summary" class="section level1">
<h1 class="hasAnchor">
<a href="#summary" class="anchor"></a>Summary</h1>
<p>In the Sheffield Tobacco Policy Model (STPM), we consider 52 adult diseases related to smoking and the corresponding relative risks of developing these diseases in current vs. never smokers, and in former smokers according to the time since they quit <span class="citation">(Webster et al. <a href="#ref-Webster2018">2018</a>)</span>. For current smokers, we assume that the relative risks of disease are the same for all smokers regardless of the amount currently smoked and the length of time as a smoker. We limit ourselves to diseases that affect the consumer themselves e.g. excluding secondary effects of smoking.</p>
</div>
<div id="disease-list" class="section level1">
<h1 class="hasAnchor">
<a href="#disease-list" class="anchor"></a>Disease list</h1>
<p>We arrived at our disease list and the corresponding International Classification of Diseases version 10 (ICD-10) definitions through an iterative process of reviewing the diseases considered by previous health economic models of smoking, and reviewing reports and papers that reviewed the disease risks of smoking. The main UK focused modelling of smoking is the NICE Tobacco Return on Investment Tool <span class="citation">(Pokhrel et al. <a href="#ref-Pokhrel2013">2013</a>)</span>, and the national monitoring of the health costs of smoking <span class="citation">(Callum and White <a href="#ref-Callum2004">2004</a>; NHS Digital <a href="#ref-Digital2018">2018</a>)</span>. In 2014, the US Surgeon General conducted a review of the diseases related to smoking, taking careful consideration of the strength of evidence for causality <span class="citation">(US Surgeon General <a href="#ref-General2014">2014</a>)</span>. In 2015, Carter et al <span class="citation">(<a href="#ref-Carter2015">2015</a>)</span> in the New England Journal of Medicine found statistical associations in the American Cancer Society’s Cancer Prevention II study (ACS-CPS II) between smoking and a much wider range of diseases than were previously considered smoking related. In 2018, Chapter 2 of the Royal College of Physician’s (RCP) report “Hiding in plain sight: Treating tobacco dependency in the NHS” <span class="citation">(Tobacco Advisory Group of the Royal College of Physicians <a href="#ref-RCP2018">2018</a>)</span> reviewed the current evidence for smoking–disease associations, focusing on recent meta-analyses, to produce an updated list of diseases that are caused by smoking. Subsequently, Cancer Research UK (CRUK) produced their own disease list and published sources for estimates of the relative risk of current vs. never smoking for developing cancers (in a study that considered smoking as one of a range of modifiable risk factors related to cancer) <span class="citation">(Brown et al. <a href="#ref-Brown2018">2018</a>)</span>.</p>
<p>We began to develop our list of diseases in 2015. The list was influence heavily by our involvement in Chapter 2 of the RCP report. We were then further influenced by discussions within our research group relating to updates to the list of diseases related to alcohol, their ICD-10 code definitions and the published sources of relative risk estimates. As part of these discussions for alcohol we made contact with the lead author of the CRUK paper, Dr Katrina Brown. Discussions focused particularly on the ICD-10 definitions of head and neck cancers, and oesophageal cancers. The result of these discussions was an updated list of alcohol related diseases for the Sheffield Alcohol Policy Model (SAPM) v4.0 <span class="citation">(Angus et al. <a href="#ref-Angus2018">2018</a>)</span>. In producing our list of smoking related diseases we sought to harmonise our ICD-10 definitions with those used in our alcohol modelling (particularly important since we will conduct joint modelling of tobacco and alcohol). Our list is mainly consistent with the RCP report, with most deviations being for cancers, where we have been influenced by CRUK’s work and our alcohol modelling. We explain the choices we made in the report where we initially presented our disease list <span class="citation">(Webster et al. <a href="#ref-Webster2018">2018</a>)</span>.</p>
<p>The notable omissions from our list are: Breast cancer - due to a small and statistially uncertain effect of smoking; Prostate cancer - due to a lack of published evidence for current smokers; Ovarian cancer - for which smoking only carries a risk for fully malignant mucinous ovarian cancers (13% of ovarian cancers are mucinous, and of these 57% are fully malignant) - that created large uncertainty in identifying the cases attributable to smoking using the ICD-10 definitions recorded in our mortality data and hospital episode statistics.</p>
<div id="oesophageal-cancer" class="section level2">
<h2 class="hasAnchor">
<a href="#oesophageal-cancer" class="anchor"></a>Oesophageal cancer</h2>
<p>For oesophageal cancer, our discussions with CRUK concluded that we should distinguish between adenocarcinoma (AC) and squamous cell carcinoma (SCC). However, it is not possible to distinguish these subtypes from the routinely recorded ICD-10 codes. We therefore settled on the following approach:</p>
<p>We apportion overall oesophageal cancer prevalence between AC and SCC using data on percentage prevalence by age and sex, which we were sent by Katrina Brown at CRUK. CRUK requested data direct from the UK cancer registries on the number of oesophageal SCCs. That data isn’t routinely available because it is morphology (cell type) data, whereas what is published as standard is topography (body part). Alternatively, we could distinguish SCC using the body sites ‘upper third of oesophagus’ and ‘middle third of oesophagus’ (ICD-10 codes C15.3 and C15.4) as a fairly good proxy for SCC <span class="citation">(Coupland et al. <a href="#ref-Coupland2012">2012</a>)</span>. Arnold et al <span class="citation">(<a href="#ref-Arnold2015">2015</a>)</span> also provide splits of Oesophageal cancer by subtype for Northern and Western Europe, which could be an alternative source of data (and might be the approach used in the Global Burden of Disease Study).</p>
<p>The percentages provided to us by CRUK are for 2014 for England. We therefore need to be aware that in modelling periods that are substantially earlier or later, the percentages might not hold true. Specifically, AC incidence in males has risen over time while AC incidence in females, and SCC incidence in both sexes, has remained fairly stable – so the relative proportions of AC and SCC in males have varied over time. We should also consider whether it is sensible to assume the distribution of AC and SCC in oesophageal cancer will be the same for deaths as it is for cases. Coupland et al <span class="citation">(<a href="#ref-Coupland2012">2012</a>)</span> show that 1 year and 5 year overall survival is significantly lower in SCC (1yr 30.3%, 5yr 8.3%) than in AC (5yr 36.4%, 5yr 9.4%) – though the absolute differences are quite small. So arguably there would be a slightly higher ratio of SCC:AC in deaths than in cases.</p>
<table class="table">
<caption>Our list of adult diseases related to smoking.</caption>
<colgroup>
<col width="16%">
<col width="32%">
<col width="29%">
<col width="21%">
</colgroup>
<thead><tr class="header">
<th>Category</th>
<th>Disease</th>
<th>ICD 10</th>
<th>Source</th>
</tr></thead>
<tbody>
<tr class="odd">
<td>Malignant neoplasms</td>
<td>Oral cavity</td>
<td>C00-C06</td>
<td><span class="citation">(Maasland et al. <a href="#ref-Maasland2014">2014</a>)</span></td>
</tr>
<tr class="even">
<td></td>
<td>Pharynx</td>
<td>C09, C10, C12-C14</td>
<td><span class="citation">(Gandini et al. <a href="#ref-Gandini2008">2008</a>)</span></td>
</tr>
<tr class="odd">
<td></td>
<td>Lung</td>
<td>C33, C34</td>
<td><span class="citation">(Jayes et al. <a href="#ref-Jayes2016">2016</a>)</span></td>
</tr>
<tr class="even">
<td></td>
<td>Nasopharynx sinonasal</td>
<td>C11, C30, C31</td>
<td><span class="citation">(Gandini et al. <a href="#ref-Gandini2008">2008</a>)</span></td>
</tr>
<tr class="odd">
<td></td>
<td>Larynx</td>
<td>C32</td>
<td><span class="citation">(Zuo et al. <a href="#ref-Zuo2017">2017</a>)</span></td>
</tr>
<tr class="even">
<td></td>
<td>Oesophageal (Adenocarcinoma)</td>
<td>C15</td>
<td><span class="citation">(Tramacere, La Vecchia, and Negri <a href="#ref-Tramacere2011">2011</a>)</span></td>
</tr>
<tr class="odd">
<td></td>
<td>Oesophageal (Squamous cell carcinoma)</td>
<td>C15</td>
<td><span class="citation">(Prabhu, Obi, and Rubenstein <a href="#ref-Prabhu2013">2013</a>)</span></td>
</tr>
<tr class="even">
<td></td>
<td>Stomach</td>
<td>C16</td>
<td><span class="citation">(Ordóñez-Mena et al. <a href="#ref-Ordonez-Mena2016">2016</a>)</span></td>
</tr>
<tr class="odd">
<td></td>
<td>Pancreas</td>
<td>C25</td>
<td><span class="citation">(Ordóñez-Mena et al. <a href="#ref-Ordonez-Mena2016">2016</a>)</span></td>
</tr>
<tr class="even">
<td></td>
<td>Liver</td>
<td>C22</td>
<td><span class="citation">(Lee et al. <a href="#ref-Lee2009">2009</a>)</span></td>
</tr>
<tr class="odd">
<td></td>
<td>Colorectal</td>
<td>C18-C20</td>
<td><span class="citation">(Ordóñez-Mena et al. <a href="#ref-Ordonez-Mena2016">2016</a>)</span></td>
</tr>
<tr class="even">
<td></td>
<td>Kidney</td>
<td>C64</td>
<td><span class="citation">(Cumberbatch et al. <a href="#ref-Cumberbatch2016">2016</a>)</span></td>
</tr>
<tr class="odd">
<td></td>
<td>Lower urinary tract</td>
<td>C65, C66</td>
<td><span class="citation">(Gandini et al. <a href="#ref-Gandini2008">2008</a>)</span></td>
</tr>
<tr class="even">
<td></td>
<td>Bladder</td>
<td>C67</td>
<td><span class="citation">(Osch et al. <a href="#ref-Osch2016">2016</a>)</span></td>
</tr>
<tr class="odd">
<td></td>
<td>Cervical</td>
<td>C53</td>
<td><span class="citation">(Gandini et al. <a href="#ref-Gandini2008">2008</a>)</span></td>
</tr>
<tr class="even">
<td></td>
<td>Acute myeloid leukaemia</td>
<td>C92</td>
<td><span class="citation">(Colamesta et al. <a href="#ref-Colamesta2016">2016</a>)</span></td>
</tr>
<tr class="odd">
<td>Circulatory system</td>
<td>Ischaemic heart disease</td>
<td>I20-I25</td>
<td><span class="citation">(Rostron <a href="#ref-Rostron2012">2012</a>)</span></td>
</tr>
<tr class="even">
<td></td>
<td>Haemorrhagic stroke</td>
<td>I60-I62</td>
<td><span class="citation">(Peters, Huxley, and Woodward <a href="#ref-Peters2013">2013</a>)</span></td>
</tr>
<tr class="odd">
<td></td>
<td>Ischaemic stroke</td>
<td>I63-I67</td>
<td><span class="citation">(Peters, Huxley, and Woodward <a href="#ref-Peters2013">2013</a>)</span></td>
</tr>
<tr class="even">
<td></td>
<td>Peripheral arterial disease</td>
<td>I73.9</td>
<td><span class="citation">(Lu, Mackay, and Pell <a href="#ref-Lu2014">2014</a>)</span></td>
</tr>
<tr class="odd">
<td></td>
<td>Abdominal aortic aneurysm</td>
<td>I71</td>
<td><span class="citation">(Cornuz et al. <a href="#ref-Cornuz2004">2004</a>)</span></td>
</tr>
<tr class="even">
<td></td>
<td>Venous thromboembolism</td>
<td>I26,I80-I82</td>
<td><span class="citation">(Cheng et al. <a href="#ref-Cheng2013">2013</a>)</span></td>
</tr>
<tr class="odd">
<td>Respiratory system</td>
<td>Chronic obstructive pulmonary disease</td>
<td>J40-J44,J47</td>
<td><span class="citation">(Jayes et al. <a href="#ref-Jayes2016">2016</a>)</span></td>
</tr>
<tr class="even">
<td></td>
<td>Asthma</td>
<td>J45-J46</td>
<td><span class="citation">(Jayes et al. <a href="#ref-Jayes2016">2016</a>)</span></td>
</tr>
<tr class="odd">
<td></td>
<td>Tuberculosis</td>
<td>A15-A19</td>
<td><span class="citation">(Jayes et al. <a href="#ref-Jayes2016">2016</a>)</span></td>
</tr>
<tr class="even">
<td></td>
<td>Obstructive sleep apnoea</td>
<td>G47.3</td>
<td><span class="citation">(Jayes et al. <a href="#ref-Jayes2016">2016</a>)</span></td>
</tr>
<tr class="odd">
<td></td>
<td>Pneumonia</td>
<td>J12-J18</td>
<td><span class="citation">(Tobacco Advisory Group of the Royal College of Physicians <a href="#ref-RCP2018">2018</a>)</span></td>
</tr>
<tr class="even">
<td></td>
<td>Influenza (clinically diagnosed)</td>
<td>J11</td>
<td><span class="citation">(Tobacco Advisory Group of the Royal College of Physicians <a href="#ref-RCP2018">2018</a>)</span></td>
</tr>
<tr class="odd">
<td></td>
<td>Influenza (microbiologically confirmed)</td>
<td>J09, J10</td>
<td><span class="citation">(Tobacco Advisory Group of the Royal College of Physicians <a href="#ref-RCP2018">2018</a>)</span></td>
</tr>
<tr class="even">
<td></td>
<td>Idiopathic pulmonary fibrosis</td>
<td>J84.1</td>
<td><span class="citation">(Taskar and Coultas <a href="#ref-Taskar2006">2006</a>)</span></td>
</tr>
<tr class="odd">
<td>Other</td>
<td>Diabetes</td>
<td>E11</td>
<td><span class="citation">(Pan et al. <a href="#ref-Pan2015">2015</a>)</span></td>
</tr>
<tr class="even">
<td></td>
<td>Alzheimers disease</td>
<td>G30</td>
<td><span class="citation">(Zhong et al. <a href="#ref-Zhong2015">2015</a>)</span></td>
</tr>
<tr class="odd">
<td></td>
<td>Multiple sclerosis</td>
<td>G35</td>
<td><span class="citation">(Zhang et al. <a href="#ref-Zhang2016">2016</a>)</span></td>
</tr>
<tr class="even">
<td></td>
<td>Parkinson</td>
<td>G20</td>
<td><span class="citation">(Breckenridge et al. <a href="#ref-Breckenridge2016">2016</a>)</span></td>
</tr>
<tr class="odd">
<td></td>
<td>Vascular dementia</td>
<td>F01</td>
<td><span class="citation">(Zhong et al. <a href="#ref-Zhong2015">2015</a>)</span></td>
</tr>
<tr class="even">
<td></td>
<td>All cause dementia</td>
<td>F02,F03</td>
<td><span class="citation">(Zhong et al. <a href="#ref-Zhong2015">2015</a>)</span></td>
</tr>
<tr class="odd">
<td></td>
<td>Depression</td>
<td>F32,F33</td>
<td><span class="citation">(Luger, Suls, and Vander Weg <a href="#ref-Luger2014">2014</a>)</span></td>
</tr>
<tr class="even">
<td></td>
<td>Schizophrenia</td>
<td>F20-F25</td>
<td><span class="citation">(Tobacco Advisory Group of the Royal College of Physicians <a href="#ref-RCP2018">2018</a>)</span></td>
</tr>
<tr class="odd">
<td></td>
<td>Psychosis</td>
<td>F28,F29</td>
<td><span class="citation">(Gurillo et al. <a href="#ref-Gurillo2015">2015</a>)</span></td>
</tr>
<tr class="even">
<td></td>
<td>Bulimia</td>
<td>F50.2</td>
<td><span class="citation">(Solmi et al. <a href="#ref-Solmi2016">2016</a>)</span></td>
</tr>
<tr class="odd">
<td></td>
<td>Systematic lupus erythematosis</td>
<td>M32</td>
<td><span class="citation">(Jiang, Li, and Jia <a href="#ref-Jiang2015">2015</a>)</span></td>
</tr>
<tr class="even">
<td></td>
<td>Low back pain</td>
<td>M54</td>
<td><span class="citation">(Shiri et al. <a href="#ref-Shiri2010">2010</a>)</span></td>
</tr>
<tr class="odd">
<td></td>
<td>Rheumatoid arthritis</td>
<td>M05,M06</td>
<td><span class="citation">(Di Giuseppe et al. <a href="#ref-DiGiuseppe2014">2014</a>)</span></td>
</tr>
<tr class="even">
<td></td>
<td>Psoriasis</td>
<td>L40</td>
<td><span class="citation">(Armstrong et al. <a href="#ref-Armstrong2014">2014</a>)</span></td>
</tr>
<tr class="odd">
<td></td>
<td>Age related macular degeneration</td>
<td>H35.3-H52.4</td>
<td><span class="citation">(Chakravarthy et al. <a href="#ref-Chakravarthy2010">2010</a>)</span></td>
</tr>
<tr class="even">
<td></td>
<td>Senile cataract</td>
<td>H25</td>
<td><span class="citation">(Ye et al. <a href="#ref-Ye2012">2012</a>)</span></td>
</tr>
<tr class="odd">
<td></td>
<td>Crohns disease</td>
<td>K50</td>
<td><span class="citation">(<span class="citeproc-not-found" data-reference-id="Mahid"><strong>???</strong></span>)</span></td>
</tr>
<tr class="even">
<td></td>
<td>Ulcerative colitis</td>
<td>K51</td>
<td><span class="citation">(Dias et al. <a href="#ref-Dias2015">2015</a>)</span></td>
</tr>
<tr class="odd">
<td></td>
<td>Hip fracture</td>
<td>S72.0-S72.2</td>
<td><span class="citation">(Shen et al. <a href="#ref-Shen2015">2015</a>)</span></td>
</tr>
<tr class="even">
<td></td>
<td>Chronic kidney disease</td>
<td>N18.1,N18.2,N18.3, N18.4,N18.8,N18.9</td>
<td><span class="citation">(Xia et al. <a href="#ref-Xia2017">2017</a>)</span></td>
</tr>
<tr class="odd">
<td></td>
<td>End-stage renal disease</td>
<td>N18.5,N18.0</td>
<td><span class="citation">(Xia et al. <a href="#ref-Xia2017">2017</a>)</span></td>
</tr>
<tr class="even">
<td></td>
<td>Hearing loss</td>
<td>H90,H91</td>
<td><span class="citation">(Nomura, Nakao, and Morimoto <a href="#ref-Nomura2005">2005</a>)</span></td>
</tr>
</tbody>
</table>
</div>
</div>
<div id="relative-risks-of-disease" class="section level1">
<h1 class="hasAnchor">
<a href="#relative-risks-of-disease" class="anchor"></a>Relative risks of disease</h1>
<p>From the sources given in Table 1, we extracted the relative risks of current vs. never smoking and their 95% confidence intervals. We illustrate these in Figure 1, ordered by the strength of relationship to smoking. We do not incorporate the uncertainty around these relative risks in our modelling, but this is an obvious area for improvement. We assume the equivalence of relative risks and odds ratios.</p>
<div id="dose-response-effects-of-smoking" class="section level2">
<h2 class="hasAnchor">
<a href="#dose-response-effects-of-smoking" class="anchor"></a>Dose-response effects of smoking</h2>
<p>The extent to which someone is at risk of a smoking related disease also depends on how much they smoke, and for how long they have smoked, i.e. the accumulated dose-response effects of smoking. However, we do not currently incorporate these dose-response effects. Instead we use the average differences in disease risk between people who currently smoke (to any level or history) and never smokers.</p>
<p>Not incorporating these dose-response effects of smoking into our model has two potential disadvantages for assessing the impact of tobacco control policy. First, the effects of reductions in smoking initiation cannot properly be assessed, because without tracking the accumulation of disease risk over the life course, the reduction in lifetime risk is not estimable. Second, the effects on disease risk of quitting smoking cannot be estimated accurately. This is because – when we operationalise the theory that disease risk declines gradually after quitting smoking <span class="citation">(Doll et al. <a href="#ref-Doll2004">2004</a>)</span> – we cannot accurately know the current risk faced by each newly quit individual i.e. we don’t know from what level the risk will decline. Furthermore, both these considerations have implications for our estimates of how changes to smoking initiation and quitting affect socioeconomic inequalities in disease risk – due to socioeconomic differences in the lifetime accumulation of disease risk not currently featuring in population models.</p>
<p>From our pilot searches for evidence on dose-response effects, we selected 12 illustrative studies, each for a different type of cancer <span class="citation">(Tredaniel et al. <a href="#ref-Tredaniel">1997</a>; Macacu et al. <a href="#ref-Macacu2015">2015</a>; Zou et al. <a href="#ref-Zou2014">2014</a>; Xu et al. <a href="#ref-Xu2012">2012</a>; Liang, Chen, and Giovannucci <a href="#ref-Liang2009">2009</a>, <a href="#ref-Liang2009">2009</a>; Maasland et al. <a href="#ref-Maasland2014">2014</a>; Fircanis et al. <a href="#ref-Fircanis2014">2014</a>; Osch et al. <a href="#ref-Osch2016">2016</a>; Pang et al. <a href="#ref-Pang2015">2015</a>; Gandini et al. <a href="#ref-Gandini2008">2008</a>)</span>. They show the inconsistency in reporting of exposure (current smoking intensity, duration, pack-years), level of exposure (e.g. categorical vs. continuous) and in the format that the risk relationships are reported (in one study, the information we would want to extract is not reported, so we would need to contact the authors). For cancer of the oral cavity, we did not find a meta-analysis but did find a recent and cohort study <span class="citation">(Maasland et al. <a href="#ref-Maasland2014">2014</a>)</span>, suggesting that we might have to relax our criteria to look only at meta-analyses.</p>
<div class="figure">
<img src="smoking-disease-risks_files/figure-html/rel%20risks-1.png" alt="Relative risks of disease in current vs. never smokers." width="720"><p class="caption">
Relative risks of disease in current vs. never smokers.
</p>
</div>
</div>
<div id="decline-in-risk-over-time-after-quitting-smoking" class="section level2">
<h2 class="hasAnchor">
<a href="#decline-in-risk-over-time-after-quitting-smoking" class="anchor"></a>Decline in risk over time after quitting smoking</h2>
<p>To estimate the risk of disease for former smokers we used the findings of Kontis et al. <span class="citation">(<a href="#ref-Kontis2014">2014</a>)</span>, who re-analysed the change in risk after smoking in the ACS-CPS II study from Oza et al.<span class="citation">(<a href="#ref-Oza2011">2011</a>)</span>, producing three functions to describe the decline in risk after quitting for each of cancers, cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD) (Figure 2). The estimates were informed by data on former smokers with known quit dates who were disease-free at baseline. The results show the proportion of excess relative risk remaining at each time-point since cessation.</p>
<p>In an effort to validate these estimates, we checked them against the range of estimates for laryngeal cancer, oropharyngeal cancer and oesophageal cancer found by the International Agency for Research on Cancer’s (IARC) 2007 review of the decline in risk after quitting smoking <span class="citation">(International Agency for Research on Cancer and World Health Organization <a href="#ref-IARCWHO2007">2007</a>)</span>. The results are shown in Figures 3-5. Most past studies do not treat the decline in risk after quitting as a continuous function of time, rather estimating the effect for variously defined categories of time. In some cases, risk is observed to be higher shortly after quitting for former smokers, which might indicate that the condition takes time to emerge after the damage is done by past smoking, or that these studies could have controlled better for individual heterogeneity. In general, the estimates of Kontis et al. <span class="citation">(<a href="#ref-Kontis2014">2014</a>)</span> fall within the cloud of estimates.</p>
<p>Thus, even though there is potential to improve on the ACS-CPS II evidence used by Kontis et al. <span class="citation">(<a href="#ref-Kontis2014">2014</a>)</span> (e.g. using the results of meta-analyses found through searching for the dose-response evidence), we adopt the approach of Kontis et al. <span class="citation">(<a href="#ref-Kontis2014">2014</a>)</span>.</p>
<p>However, since Kontis et al. <span class="citation">(<a href="#ref-Kontis2014">2014</a>)</span> only provide estimates for cancers, CVD or COPD, we must decide how to specify the rates of decline in the risks due to smoking after quitting for other diseases. Kontis et al. <span class="citation">(<a href="#ref-Kontis2014">2014</a>)</span> consider this issue for type II diabetes, stating that “Randomised trials also indicate that the benefits of behaviour change and pharmacological treatment on diabetes risk occur within a few years, more similar to the CVDs than cancers <span class="citation">(Knowler et al. <a href="#ref-Knowler2002">2002</a>)</span>. Therefore, we used the CVD curve for diabetes.” In-line with Kontis et al. <span class="citation">(<a href="#ref-Kontis2014">2014</a>)</span>, we apply the rate of decline in risk of CVD after quitting smoking to type 2 diabetes.</p>
<p>We have begun to develop our own further assumptions: We assume that the decline in risk for all respiratory conditions follows Kontis et al.’s <span class="citation">(<a href="#ref-Kontis2014">2014</a>)</span> estimates for COPD. For other diseases, we might assume that the decline in relative risk follows the cancer curve (the most conservative option), that the additional risk from smoking disappears immediately following quitting (the least conservative option), or that the risk immediately falls to the average risk in former smokers identified from meta-analyses (potentially a middle-ground option?). However, these assumptions are based on no or limited evidence and will need revisiting to see what use might be made of existing evidence and expert opinion to develop a credible approach.</p>
<div class="figure">
<img src="smoking-disease-risks_files/figure-html/tob%20lags-1.png" alt="Rate at which the excess risk of disease due to smoking declines over time after quitting." width="436.8"><p class="caption">
Rate at which the excess risk of disease due to smoking declines over time after quitting.
</p>
</div>
<div class="figure">
<img src="smoking-disease-risks_files/figure-html/tob%20lags%20IARC%20comparison%20laryngeal-1.png" alt="Comparison of decline in cancer risk after quitting to results of IARC review for Laryngeal cancers." width="720"><p class="caption">
Comparison of decline in cancer risk after quitting to results of IARC review for Laryngeal cancers.
</p>
</div>
<div class="figure">
<img src="smoking-disease-risks_files/figure-html/tob%20lags%20IARC%20comparison%20Oropharyngeal-1.png" alt="Comparison of decline in cancer risk after quitting to results of IARC review for Oropharyngeal." width="720"><p class="caption">
Comparison of decline in cancer risk after quitting to results of IARC review for Oropharyngeal.
</p>
</div>
<div class="figure">
<img src="smoking-disease-risks_files/figure-html/tob%20lags%20IARC%20comparison%20oesophageal-1.png" alt="Comparison of decline in cancer risk after quitting to results of IARC review for Oesophageal cancers." width="720"><p class="caption">
Comparison of decline in cancer risk after quitting to results of IARC review for Oesophageal cancers.
</p>
</div>
</div>
</div>
<div id="use-of-relative-risks-in-stpm" class="section level1">
<h1 class="hasAnchor">
<a href="#use-of-relative-risks-in-stpm" class="anchor"></a>Use of relative risks in STPM</h1>
<p>The functions to assign relative risks to each individual based on their current or former smoking status are in the <code>tobalcepi</code> R package, which is part of the set of R packages containing the code that underlies STPM.</p>
<p>The function <code><a href="../reference/RRFunc.html">RRFunc()</a></code> does the job of assigning the relative risks of each disease to a sample of individuals according to their current tobacco consumption status. Since STPM is a part of our joint programme of modelling across tobacco and alcohol, <code><a href="../reference/RRFunc.html">RRFunc()</a></code> has options that can tailor it to assign risks based on tobacco consumption only, alcohol consumption only, or both tobacco and alcohol consumption.</p>
<p>For tobacco, the relative risk for each individual is calculated based on whether they are a current, former or never smoker. Currently, all current smokers have the same relative risk regardless of the amount they currently smoke or have smoked in the past. Former smokers are initially given the relative risk associated with current smokers, which we then scale according to a disease-specific function that describes how risk declines after quitting smoking.</p>
<p>The first step carried out by <code><a href="../reference/RRFunc.html">RRFunc()</a></code> is to assign both current and former smokers the relative risk for each disease associated with current smoking. It does this using the function <code>RRTob()</code>. For former smokers, we estimate the risk in former smokers using the equation</p>
<p><span class="math display">\[\begin{equation}
R_{former}=1+[R_{current}-1][1-p(t)],  
\end{equation}\]</span></p>
<p>in which the relative risk (<span class="math inline">\(R\)</span>) associated with current smoking is scaled according to our estimates of the proportional reduction in the risk (<span class="math inline">\(p\)</span>) associated with their number of years (<span class="math inline">\(t\)</span>) as a former smoker. After someone has been quit for 40 years, we assume their risk reverts back to be the same as a never smoker.</p>
<p>The current version of STPM models the individual-level dynamics of smoking and the associated risks of disease, but it links these to the population-level trends in the rates of morbidity and mortality from each disease. In other words, STPM models the direct link between smoking and disease prevalence rather than modelling the link between smoking and disease incidence (which would then have a knock-on effect to prevalence).</p>
<p>We define the effect of an intervention on the rates of disease morbidity and mortality in terms of a proportional change, stratified by year, age, sex and quintiles of the Index of Multiple Deprivation. The proportional change is the ratio of the average risks in each of these subgroups in the treatment compared to the control arms of the model (see the STPM vignette for further details). This proportional change is also known as the ‘potential impact fraction’ (<em>PIF = ratio of weighted average revised risk given a policy to the weighted average baseline risk given current consumption levels</em>). The PIF approach to updating the population-level rates of morbidity and mortality originated in the <em>PREVENT</em> model <span class="citation">(Gunningschepers <a href="#ref-Gunningschepers1989">1989</a>)</span> and was extend to underlie the Sheffield Alcohol Policy Model <span class="citation">(Brennan et al. <a href="#ref-Brennan2015">2015</a>)</span>.</p>
<p>Thus, after assigning each individual (<span class="math inline">\(i\)</span>) a relative risk for each disease (<span class="math inline">\(h\)</span>) based on their current smoking status, we then calculate the average risk (<span class="math inline">\(\bar{R}\)</span>) across the <span class="math inline">\(N\)</span> individuals in each subgroup (<span class="math inline">\(s\)</span>)</p>
<p><span class="math display">\[\begin{equation}
\bar{R}_s^h= \frac{1}{N_s}\sum_{i\in{s}}R^h_i.  
\end{equation}\]</span></p>
<p>This average risk is calculated by the function <code><a href="../reference/subgroupRisk.html">subgroupRisk()</a></code>. The functon <code>UpdateHarm()</code> in the <code>stapmr</code> R package calculates and applies the PIF.</p>
<p>The <code>tobalcepi</code> package contains data on smoking from the Health Survey for England, 2001-2016 in <code>hse_data_smoking</code>. To illustrate, we take a subset of 10,000 individuals from these data, assign them their smoking attributable relative risks for laryngeal cancer, and calculate the average risk for males and females.</p>
</div>
<div id="code-developments" class="section level1">
<h1 class="hasAnchor">
<a href="#code-developments" class="anchor"></a>Code developments</h1>
<p>To integrate dose-response risk functions into our modelling, we have started to develop a new function to replace <code><a href="../reference/RRtob.html">RRtob()</a></code>. The function <code>RRTobDR</code> estimates each individual in the data their dose-response relative risk based on the number of cigarettes they consume per day. This function has not yet been integrated into the function <code><a href="../reference/RRFunc.html">RRFunc()</a></code>.</p>
<p>In order to this this we need to work out if and how we assign risk to former smokers, as there is no cigs per day information for former smokers.</p>
</div>
<div id="references" class="section level1 unnumbered">
<h1 class="hasAnchor">
<a href="#references" class="anchor"></a>References</h1>
<div id="refs" class="references">
<div id="ref-Angus2018">
<p>Angus, Colin, M Henney, L Webster, and Duncan Gillespie. 2018. <em>Alcohol-Attributable Diseases and Dose-Response Curves for the Sheffield Alcohol Policy Model Version 4.0</em>. Book. <a href="https://doi.org/10.15131/shef.data.6819689.v1">https://doi.org/10.15131/shef.data.6819689.v1</a>.</p>
</div>
<div id="ref-Armstrong2014">
<p>Armstrong, A. W., C. T. Harskamp, J. S. Dhillon, and E. J. Armstrong. 2014. “Psoriasis and Smoking: A Systematic Review and Meta-Analysis.” Journal Article. <em>Br J Dermatol</em> 170 (2): 304–14. <a href="https://doi.org/10.1111/bjd.12670">https://doi.org/10.1111/bjd.12670</a>.</p>
</div>
<div id="ref-Arnold2015">
<p>Arnold, Melina, Isabelle Soerjomataram, Jacques Ferlay, and David Forman. 2015. “Global Incidence of Oesophageal Cancer by Histological Subtype in 2012.” Journal Article. <em>Gut</em> 64 (3): 381–87.</p>
</div>
<div id="ref-Breckenridge2016">
<p>Breckenridge, Charles B., Colin Berry, Ellen T. Chang, Jr. Sielken Robert L., and Jack S. Mandel. 2016. “Association Between Parkinson’s Disease and Cigarette Smoking, Rural Living, Well-Water Consumption, Farming and Pesticide Use: Systematic Review and Meta-Analysis.” Journal Article. <em>PLOS ONE</em> 11 (4): e0151841. <a href="https://doi.org/10.1371/journal.pone.0151841">https://doi.org/10.1371/journal.pone.0151841</a>.</p>
</div>
<div id="ref-Brennan2015">
<p>Brennan, Alan, Petra Meier, Robin Purshouse, Rachid Rafia, Yang Meng, Daniel Hill-Macmanus, Colin Angus, and John Holmes. 2015. “The Sheffield Alcohol Policy Model – a Mathematical Description.” Journal Article. <em>Health Economics</em> 24 (10): 1368–88. <a href="https://doi.org/10.1002/hec.3105">https://doi.org/10.1002/hec.3105</a>.</p>
</div>
<div id="ref-Brown2018">
<p>Brown, Katrina F., Harriet Rumgay, Casey Dunlop, Margaret Ryan, Frances Quartly, Alison Cox, Andrew Deas, et al. 2018. “The Fraction of Cancer Attributable to Modifiable Risk Factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015.” Journal Article. <em>British Journal of Cancer</em> 118 (8): 1130–41. <a href="https://doi.org/10.1038/s41416-018-0029-6">https://doi.org/10.1038/s41416-018-0029-6</a>.</p>
</div>
<div id="ref-Callum2004">
<p>Callum, Christine, and Patti White. 2004. <em>Tobacco in London: The Preventable Burden</em>. Book. SmokeFree London.</p>
</div>
<div id="ref-Carter2015">
<p>Carter, Brian D., Christian C. Abnet, Diane Feskanich, Neal D. Freedman, Patricia Hartge, Cora E. Lewis, Judith K. Ockene, et al. 2015. “Smoking and Mortality - Beyond Established Causes.” Journal Article. <em>New England Journal of Medicine</em> 372 (7): 631–40. <a href="https://doi.org/10.1056/NEJMsa1407211">https://doi.org/10.1056/NEJMsa1407211</a>.</p>
</div>
<div id="ref-Chakravarthy2010">
<p>Chakravarthy, Usha, Tien Y Wong, Astrid Fletcher, Elisabeth Piault, Christopher Evans, Gergana Zlateva, Ronald Buggage, Andreas Pleil, and Paul Mitchell. 2010. “Clinical Risk Factors for Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis.” Journal Article. <em>BMC Ophthalmology</em> 10 (1): 31.</p>
</div>
<div id="ref-Cheng2013">
<p>Cheng, Yun-Jiu, Zhi-Hao Liu, Feng-Juan Yao, Wu-Tao Zeng, Dong-Dan Zheng, Yu-Gang Dong, and Su-Hua Wu. 2013. “Current and Former Smoking and Risk for Venous Thromboembolism: A Systematic Review and Meta-Analysis.” Journal Article. <em>PLoS Medicine</em> 10 (9): e1001515.</p>
</div>
<div id="ref-Colamesta2016">
<p>Colamesta, Vittoria, Silvia D’Aguanno, Massimo Breccia, Sara Bruffa, Claudio Cartoni, and Giuseppe La Torre. 2016. “Do the Smoking Intensity and Duration, the Years Since Quitting, the Methodological Quality and the Year of Publication of the Studies Affect the Results of the Meta-Analysis on Cigarette Smoking and Acute Myeloid Leukemia (Aml) in Adults?” Journal Article. <em>Critical Reviews in Oncology/Hematology</em> 99: 376–88.</p>
</div>
<div id="ref-Cornuz2004">
<p>Cornuz, Jacques, Claudio Sidoti Pinto, Heindrik Tevaearai, and Matthias Egger. 2004. “Risk Factors for Asymptomatic Abdominal Aortic Aneurysm: Systematic Review and Meta-Analysis of Population-Based Screening Studies.” Journal Article. <em>The European Journal of Public Health</em> 14 (4): 343–49.</p>
</div>
<div id="ref-Coupland2012">
<p>Coupland, V. H., W. Allum, J. M. Blazeby, M. A. Mendall, R. H. Hardwick, K. M. Linklater, H. Moller, and E. A. Davies. 2012. “Incidence and Survival of Oesophageal and Gastric Cancer in England Between 1998 and 2007, a Population-Based Study.” Journal Article. <em>BMC Cancer</em> 12: 11. <a href="https://doi.org/10.1186/1471-2407-12-11">https://doi.org/10.1186/1471-2407-12-11</a>.</p>
</div>
<div id="ref-Cumberbatch2016">
<p>Cumberbatch, Marcus G, Matteo Rota, James WF Catto, and Carlo La Vecchia. 2016. “The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-Analysis of Incidence and Mortality Risks.” Journal Article. <em>European Urology</em> 70 (3): 458–66.</p>
</div>
<div id="ref-Dias2015">
<p>Dias, C. C., P. P. Rodrigues, A. da Costa-Pereira, and F. Magro. 2015. “Clinical Predictors of Colectomy in Patients with Ulcerative Colitis: Systematic Review and Meta-Analysis of Cohort Studies.” Journal Article. <em>J Crohns Colitis</em> 9 (2): 156–63. <a href="https://doi.org/10.1093/ecco-jcc/jju016">https://doi.org/10.1093/ecco-jcc/jju016</a>.</p>
</div>
<div id="ref-DiGiuseppe2014">
<p>Di Giuseppe, Daniela, Andrea Discacciati, Nicola Orsini, and Alicja Wolk. 2014. “Cigarette Smoking and Risk of Rheumatoid Arthritis: A Dose-Response Meta-Analysis.” Journal Article. <em>Arthritis Research &amp; Therapy</em> 16 (2): R61.</p>
</div>
<div id="ref-Doll2004">
<p>Doll, Richard, Richard Peto, Jillian Boreham, and Isabelle Sutherland. 2004. “Mortality in Relation to Smoking: 50 Years’ Observations on Male British Doctors.” Journal Article. <em>Bmj</em> 328 (7455): 1519.</p>
</div>
<div id="ref-Fircanis2014">
<p>Fircanis, Sophia, Priscilla Merriam, Naushaba Khan, and Jorge J Castillo. 2014. “The Relation Between Cigarette Smoking and Risk of Acute Myeloid Leukemia: An Updated Meta‐analysis of Epidemiological Studies.” Journal Article. <em>American Journal of Hematology</em> 89 (8): E125–E132.</p>
</div>
<div id="ref-Gandini2008">
<p>Gandini, Sara, Edoardo Botteri, Simona Iodice, Mathieu Boniol, Albert B Lowenfels, Patrick Maisonneuve, and Peter Boyle. 2008. “Tobacco Smoking and Cancer: A Meta‐analysis.” Journal Article. <em>International Journal of Cancer</em> 122 (1): 155–64. <a href="https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.23033">https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.23033</a>.</p>
</div>
<div id="ref-Gunningschepers1989">
<p>Gunningschepers, L. 1989. “The Health Benefits of Preventions - a Simulation Approach.” Journal Article. <em>Health Policy</em> 12 (1-2): 1–255. <a href="&lt;Go%20to%20ISI&gt;://WOS:A1989AD34000001">&lt;Go to ISI&gt;://WOS:A1989AD34000001</a>.</p>
</div>
<div id="ref-Gurillo2015">
<p>Gurillo, Pedro, Sameer Jauhar, Robin M. Murray, and James H. MacCabe. 2015. “Does Tobacco Use Cause Psychosis? Systematic Review and Meta-Analysis.” Journal Article. <em>The Lancet Psychiatry</em> 2 (8): 718–25. <a href="https://doi.org/10.1016/S2215-0366(15)00152-2">https://doi.org/10.1016/S2215-0366(15)00152-2</a>.</p>
</div>
<div id="ref-IARCWHO2007">
<p>International Agency for Research on Cancer and World Health Organization. 2007. “Reversal of Risk After Quitting Smoking.” Report.</p>
</div>
<div id="ref-Jayes2016">
<p>Jayes, Leah, Patricia L. Haslam, Christina G. Gratziou, Pippa Powell, John Britton, Constantine Vardavas, Carlos Jimenez-Ruiz, and Jo Leonardi-Bee. 2016. “SmokeHaz: Systematic Reviews and Meta-Analyses of the Effects of Smoking on Respiratory Health.” Journal Article. <em>CHEST Journal</em> 150 (1): 164–79.</p>
</div>
<div id="ref-Jiang2015">
<p>Jiang, Fan, Suyun Li, and Chongqi Jia. 2015. “Smoking and the Risk of Systemic Lupus Erythematosus: An Updated Systematic Review and Cumulative Meta-Analysis.” Journal Article. <em>Clinical Rheumatology</em> 34 (11): 1885–92.</p>
</div>
<div id="ref-Knowler2002">
<p>Knowler, William C, Elizabeth Barrett-Connor, Sarah E Fowler, Richard F Hamman, John M Lachin, Elizabeth A Walker, and David M Nathan. 2002. “Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin.” Journal Article. <em>The New England Journal of Medicine</em> 346 (6): 393–403.</p>
</div>
<div id="ref-Kontis2014">
<p>Kontis, Vasilis, Colin D Mathers, Jürgen Rehm, Gretchen A Stevens, Kevin D Shield, Ruth Bonita, Leanne M Riley, Vladimir Poznyak, Robert Beaglehole, and Majid Ezzati. 2014. “Contribution of Six Risk Factors to Achieving the 25× 25 Non-Communicable Disease Mortality Reduction Target: A Modelling Study.” Journal Article. <em>The Lancet</em> 384 (9941): 427–37.</p>
</div>
<div id="ref-Lee2009">
<p>Lee, Yuan-Chin Amy, Catherine Cohet, Yu-Ching Yang, Leslie Stayner, Mia Hashibe, and Kurt Straif. 2009. “Meta-Analysis of Epidemiologic Studies on Cigarette Smoking and Liver Cancer.” Journal Article. <em>International Journal of Epidemiology</em> 38 (6): 1497–1511.</p>
</div>
<div id="ref-Liang2009">
<p>Liang, PS, TY Chen, and E Giovannucci. 2009. “Cigarette Smoking and Colorectal Cancer Incidence and Mortality: Systematic Review and Meta-Analysis.” Journal Article. <em>International Journal of Cancer</em> 124 (10): 2406–15. <a href="https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.24191">https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.24191</a>.</p>
</div>
<div id="ref-Lu2014">
<p>Lu, L, DF Mackay, and JP Pell. 2014. “Meta-Analysis of the Association Between Cigarette Smoking and Peripheral Arterial Disease.” Journal Article. <em>Heart</em> 100 (5): 414–23.</p>
</div>
<div id="ref-Luger2014">
<p>Luger, Tana M., Jerry Suls, and Mark W. Vander Weg. 2014. “How Robust Is the Association Between Smoking and Depression in Adults? A Meta-Analysis Using Linear Mixed-Effects Models.” Journal Article. <em>Addictive Behaviors</em> 39 (10): 1418–29. <a href="https://doi.org/http://doi.org/10.1016/j.addbeh.2014.05.011">https://doi.org/http://doi.org/10.1016/j.addbeh.2014.05.011</a>.</p>
</div>
<div id="ref-Maasland2014">
<p>Maasland, Denise HE, Piet A van den Brandt, Bernd Kremer, R Alexandra Sandra Goldbohm, and Leo J Schouten. 2014. “Alcohol Consumption, Cigarette Smoking and the Risk of Subtypes of Head-Neck Cancer: Results from the Netherlands Cohort Study.” Journal Article. <em>BMC Cancer</em> 14 (1): 187.</p>
</div>
<div id="ref-Macacu2015">
<p>Macacu, A., P. Autier, M. Boniol, and P. Boyle. 2015. “Active and Passive Smoking and Risk of Breast Cancer: A Meta-Analysis.” Journal Article. <em>Breast Cancer Research and Treatment</em> 154 (2): 213–24. <a href="https://doi.org/10.1007/s10549-015-3628-4">https://doi.org/10.1007/s10549-015-3628-4</a>.</p>
</div>
<div id="ref-Digital2018">
<p>NHS Digital. 2018. “Statistics on Smoking: England, 2018.” Report.</p>
</div>
<div id="ref-Nomura2005">
<p>Nomura, Kyoko, Mutsuhiro Nakao, and Takeshi Morimoto. 2005. “Effect of Smoking on Hearing Loss: Quality Assessment and Meta-Analysis.” Journal Article. <em>Preventive Medicine</em> 40 (2): 138–44.</p>
</div>
<div id="ref-Ordonez-Mena2016">
<p>Ordóñez-Mena, José Manuel, Ben Schöttker, Ute Mons, Mazda Jenab, Heinz Freisling, Bas Bueno-de-Mesquita, Mark G O’Doherty, Angela Scott, Frank Kee, and Bruno H Stricker. 2016. “Quantification of the Smoking-Associated Cancer Risk with Rate Advancement Periods: Meta-Analysis of Individual Participant Data from Cohorts of the Chances Consortium.” Journal Article. <em>BMC Medicine</em> 14 (1): 62.</p>
</div>
<div id="ref-Osch2016">
<p>Osch, Frits HM van, Sylvia HJ Jochems, Frederik-Jan van Schooten, Richard T Bryan, and Maurice P Zeegers. 2016. “Quantified Relations Between Exposure to Tobacco Smoking and Bladder Cancer Risk: A Meta-Analysis of 89 Observational Studies.” Journal Article. <em>International Journal of Epidemiology</em> 45 (3): 857–70.</p>
</div>
<div id="ref-Oza2011">
<p>Oza, Shefali, Michael J Thun, S Jane Henley, Alan D Lopez, and Majid Ezzati. 2011. “How Many Deaths Are Attributable to Smoking in the United States? Comparison of Methods for Estimating Smoking-Attributable Mortality When Smoking Prevalence Changes.” Journal Article. <em>Preventive Medicine</em> 52 (6): 428–33.</p>
</div>
<div id="ref-Pan2015">
<p>Pan, An, Yeli Wang, Mohammad Talaei, Frank B Hu, and Tangchun Wu. 2015. “Relation of Active, Passive, and Quitting Smoking with Incident Type 2 Diabetes: A Systematic Review and Meta-Analysis.” Journal Article. <em>The Lancet Diabetes &amp; Endocrinology</em> 3 (12): 958–67.</p>
</div>
<div id="ref-Pang2015">
<p>Pang, Q., K. Qu, J. Zhang, X. Xu, S. Liu, S. Song, R. Wang, L. Zhang, Z. Wang, and C. Liu. 2015. “Cigarette Smoking Increases the Risk of Mortality from Liver Cancer: A Clinical-Based Cohort and Meta-Analysis.” Journal Article. <em>Journal of Gastroenterology &amp; Hepatology</em> 30 (10): 1450–60.</p>
</div>
<div id="ref-Peters2013">
<p>Peters, Sanne AE, Rachel R Huxley, and Mark Woodward. 2013. “Smoking as a Risk Factor for Stroke in Women Compared with Men: A Systematic Review and Meta-Analysis of 81 Cohorts, Including 3 980 359 Individuals and 42 401 Strokes.” Journal Article. <em>Stroke</em> 44 (10): 2821–8.</p>
</div>
<div id="ref-Pokhrel2013">
<p>Pokhrel, S., L. Owen, A. Lester-George, K. Coyle, Coyle D., West R., Trapero-Bertran M., and Meads C. 2013. “Tobacco Control Return on Investment Tool.” Report. National Institute for Health; Care Excellence.</p>
</div>
<div id="ref-Prabhu2013">
<p>Prabhu, A, KO Obi, and JH Rubenstein. 2013. “Systematic Review with Meta‐analysis: Race‐specific Effects of Alcohol and Tobacco on the Risk of Oesophageal Squamous Cell Carcinoma.” Journal Article. <em>Alimentary Pharmacology &amp; Therapeutics</em> 38 (10): 1145–55.</p>
</div>
<div id="ref-Rostron2012">
<p>Rostron, Brian. 2012. “Smoking-Attributable Mortality by Cause in the United States: Revising the Cdc’s Data and Estimates.” Journal Article. <em>Nicotine &amp; Tobacco Research</em> 15 (1): 238–46.</p>
</div>
<div id="ref-Shen2015">
<p>Shen, Guang Si, Yong Li, GuoYang Zhao, Hai Bin Zhou, Zong Gang Xie, Wei Xu, Hai Nan Chen, Qi Rong Dong, and You Jia Xu. 2015. “Cigarette Smoking and Risk of Hip Fracture in Women: A Meta-Analysis of Prospective Cohort Studies.” Journal Article. <em>Injury</em> 46 (7): 1333–40.</p>
</div>
<div id="ref-Shiri2010">
<p>Shiri, Rahman, Jaro Karppinen, Päivi Leino-Arjas, Svetlana Solovieva, and Eira Viikari-Juntura. 2010. “The Association Between Smoking and Low Back Pain: A Meta-Analysis.” Journal Article. <em>The American Journal of Medicine</em> 123 (1): 87. e7–87. e35.</p>
</div>
<div id="ref-Solmi2016">
<p>Solmi, Marco, Nicola Veronese, Giuseppe Sergi, Claudio Luchini, Angela Favaro, Paolo Santonastaso, Davy Vancampfort, et al. 2016. “The Association Between Smoking Prevalence and Eating Disorders: A Systematic Review and Meta-Analysis.” Journal Article. <em>Addiction</em> 111 (11): 1914–22. <a href="https://doi.org/10.1111/add.13457">https://doi.org/10.1111/add.13457</a>.</p>
</div>
<div id="ref-Taskar2006">
<p>Taskar, Varsha S, and David B Coultas. 2006. “Is Idiopathic Pulmonary Fibrosis an Environmental Disease?” Journal Article. <em>Proceedings of the American Thoracic Society</em> 3 (4): 293–98.</p>
</div>
<div id="ref-RCP2018">
<p>Tobacco Advisory Group of the Royal College of Physicians. 2018. “Hiding in plain sight: Treating tobacco dependency in the NHS.” Research report. <em>Available from: Https://Www.rcplondon.ac.uk/Projects/Outputs/Hiding-Plain-Sight-Treating-Tobacco-Dependency-Nhs</em>.</p>
</div>
<div id="ref-Tramacere2011">
<p>Tramacere, Irene, Carlo La Vecchia, and Eva Negri. 2011. “Brief Report: Tobacco Smoking and Esophageal and Gastric Cardia Adenocarcinoma: A Meta-Analysis.” Journal Article. <em>Epidemiology</em>, 344–49.</p>
</div>
<div id="ref-Tredaniel">
<p>Tredaniel, J., P. Boffetta, E. Buiatti, R. Saracci, and A. Hirsch. 1997. “Tobacco Smoking and Gastric Cancer: Review and Meta-Analysis.” Journal Article. <em>International Journal of Cancer</em> 72 (4): 565–73. <a href="https://onlinelibrary.wiley.com/doi/pdf/10.1002/%28SICI%291097-0215%2819970807%2972%3A4%3C565%3A%3AAID-IJC3%3E3.0.CO%3B2-O">https://onlinelibrary.wiley.com/doi/pdf/10.1002/%28SICI%291097-0215%2819970807%2972%3A4%3C565%3A%3AAID-IJC3%3E3.0.CO%3B2-O</a>.</p>
</div>
<div id="ref-General2014">
<p>US Surgeon General. 2014. “The Health Consequences of Smoking–50 Years of Progress: A Report of the Surgeon General. US Department of Health and Human Services, Centers for Disease Control and Prevention.” Journal Article. <em>National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health</em>.</p>
</div>
<div id="ref-Webster2018">
<p>Webster, L, C Angus, A Brennan, and D. Gillespie. 2018. “Smoking and the Risks of Adult Diseases.” Journal Article.</p>
</div>
<div id="ref-Xia2017">
<p>Xia, Jia, Lin Wang, Zhiheng Ma, Liping Zhong, Ying Wang, Yachan Gao, Liqun He, and Xiao Su. 2017. “Cigarette Smoking and Chronic Kidney Disease in the General Population: A Systematic Review and Meta-Analysis of Prospective Cohort Studies.” Journal Article. <em>Nephrology Dialysis Transplantation</em> 32 (3): 475–87.</p>
</div>
<div id="ref-Xu2012">
<p>Xu, F. H., D. Xiong, Y. F. Xu, S. M. Cao, W. Q. Xue, H. D. Qin, W. S. Liu, et al. 2012. “An Epidemiological and Molecular Study of the Relationship Between Smoking, Risk of Nasopharyngeal Carcinoma, and Epsteinbarr Virus Activation.” Journal Article. <em>Jnci-Journal of the National Cancer Institute</em> 104 (18): 1396–1410. <a href="https://doi.org/10.1093/jnci/djs320">https://doi.org/10.1093/jnci/djs320</a>.</p>
</div>
<div id="ref-Ye2012">
<p>Ye, Juan, Jinjing He, Changjun Wang, Han Wu, Xin Shi, Huina Zhang, Jiajun Xie, and Sang Yeul Lee. 2012. “Smoking and Risk of Age-Related Cataract: A Meta-Analysis.” Journal Article. <em>Investigative Ophthalmology &amp; Visual Science</em> 53 (7): 3885–95.</p>
</div>
<div id="ref-Zhang2016">
<p>Zhang, Peng, Rui Wang, Zhijun Li, Yuhan Wang, Chunshi Gao, Xin Lv, Yuanyuan Song, and Bo Li. 2016. “The Risk of Smoking on Multiple Sclerosis: A Meta-Analysis Based on 20,626 Cases from Case-Control and Cohort Studies.” Journal Article. <em>PeerJ</em> 4: e1797.</p>
</div>
<div id="ref-Zhong2015">
<p>Zhong, Guochao, Yi Wang, Yong Zhang, Jeff Jianfei Guo, and Yong Zhao. 2015. “Smoking Is Associated with an Increased Risk of Dementia: A Meta-Analysis of Prospective Cohort Studies with Investigation of Potential Effect Modifiers.” Journal Article. <em>PLoS One</em> 10 (3): e0118333.</p>
</div>
<div id="ref-Zou2014">
<p>Zou, L., R. Zhong, N. Shen, W. Chen, B. Zhu, J. Ke, X. Lu, et al. 2014. “Non-Linear Dose-Response Relationship Between Cigarette Smoking and Pancreatic Cancer Risk: Evidence from a Meta-Analysis of 42 Observational Studies.” Journal Article. <em>European Journal of Cancer</em> 50 (1): 193–203.</p>
</div>
<div id="ref-Zuo2017">
<p>Zuo, Jing-Jing, Ze-Zhang Tao, Chen Chen, Zhang-Wei Hu, Ye-Xing Xu, An-Yuan Zheng, and Yi Guo. 2017. “Characteristics of Cigarette Smoking Without Alcohol Consumption and Laryngeal Cancer: Overall and Time-Risk Relation. A Meta-Analysis of Observational Studies.” Journal Article. <em>European Archives of Oto-Rhino-Laryngology</em> 274 (3): 1617–31.</p>
</div>
</div>
</div>
  </div>

  <div class="col-md-3 hidden-xs hidden-sm" id="pkgdown-sidebar">

        <nav id="toc" data-toggle="toc"><h2 data-toc-skip>Contents</h2>
    </nav>
</div>

</div>



      <footer><div class="copyright">
  <p>Developed by <a href="https://www.sheffield.ac.uk/scharr/sections/heds/staff/gillespie_d">Duncan Gillespie</a>, Laura Webster, <a href="https://www.sheffield.ac.uk/scharr/sections/heds/staff/henney_m">Maddy Henney</a>, <a href="https://www.sheffield.ac.uk/scharr/sections/heds/staff/angus_c">Colin Angus</a>, <a href="https://www.sheffield.ac.uk/scharr/sections/heds/staff/brennan_a">Alan Brennan</a>.</p>
</div>

<div class="pkgdown">
  <p>Site built with <a href="https://pkgdown.r-lib.org/">pkgdown</a> 1.5.1.</p>
</div>

      </footer>
</div>

  


  </body>
</html>
